Loracarbef Anhydrous
A anhydrous salt form of loracarbef with the same therapeutic properties. A carbacephem antibiotic, structurally similar to second-generation cephalosporins, used to treat mild to moderate respiratory, urinary, and skin infections caused by susceptible bacteria.
Moleküler Ağırlık
349,7700 g/mol
LogP
-1,70
TPSA
113,00 Ų
Lipinski RO5
Geçer
Etki Mekanizması
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
2D Yapı
Cite this structure
Embed this structure
SMILES
N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CC[C@H]12)c1ccccc1
InChI
InChI=1S/C16H16ClN3O4/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24)/t10-,11-,12+/m1/s1
Molecular Formula
C16H16ClN3O4
HBD / HBA
3 / 5
Döndürülebilir Bağlar
4
Ağır Atomlar
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A anhydrous salt form of loracarbef with the same therapeutic properties. A carbacephem antibiotic, structurally similar to second-generation cephalosporins, used to treat mild to moderate respiratory, urinary, and skin infections caused by susceptible bacteria.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Loracarbef Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1013. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5284585. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="loracarbef-anhydrous"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/loracarbef-anhydrous/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/loracarbef-anhydrous/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/loracarbef-anhydrous/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="loracarbef-anhydrous"></drugfyi-drug>